These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 16410679

  • 1. Ribavirin levels and haemoglobin decline in early virological responders and non-responders to hepatitis C virus combination therapy.
    Donnerer J, Grahovac M, Stelzl E, Kessler HH, Bankuti C, Stadlbauer V, Stauber RE.
    Pharmacology; 2006; 76(3):136-40. PubMed ID: 16410679
    [Abstract] [Full Text] [Related]

  • 2. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF, Fuentes AP, Olivera-Martinez MA, Gutiérrez-Reyes G, Cortina D, Oregel JA, Pérez-Pruna C, Sixtos MS, Cruz-Castellanos S, Soto-Ramírez LE, Rodríguez-Díaz R, Fuentes-Romero L, Gutiérrez-Ruiz MC, Kershenobich D.
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [Abstract] [Full Text] [Related]

  • 3. Early hepatitis C virus changes and sustained response in patients with chronic hepatitis C treated with peginterferon alpha-2b and ribavirin.
    Gallegos-Orozco JF, Loaeza-del Castillo A, Fuentes AP, García-Sandoval M, Soto L, Rodríguez R, Gutiérrez-Ruíz MC, Gutiérrez-Reyes G, Bonder A, Olivera MA, Kershenobich D.
    Liver Int; 2005 Feb; 25(1):91-5. PubMed ID: 15698404
    [Abstract] [Full Text] [Related]

  • 4. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
    Tsubota A, Arase Y, Someya T, Suzuki Y, Suzuki F, Saitoh S, Ikeda K, Akuta N, Hosaka T, Kobayashi M, Kumada H.
    J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness and tolerability of pegylated Interferon alpha-2a and ribavirin combination therapy in Romanian patients with chronic hepatitis C: from clinical trials to clinical practice.
    Gheorghe L, Grigorescu M, Iacob S, Damian D, Gheorghe C, Iacob R, Simionov I, Vadan R, Parvulescu I, Bancila I.
    Rom J Gastroenterol; 2005 Jun; 14(2):109-15. PubMed ID: 15990928
    [Abstract] [Full Text] [Related]

  • 6. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
    Yu JW, Wang GQ, Sun LJ, Li XG, Li SC.
    J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
    [Abstract] [Full Text] [Related]

  • 7. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection.
    Ferenci P, Formann E, Laferl H, Gschwantler M, Hackl F, Brunner H, Hubmann R, Datz C, Stauber R, Steindl-Munda P, Kessler HH, Klingler A, Gangl A, Austrian Hepatitis Study Group.
    J Hepatol; 2006 Feb; 44(2):275-82. PubMed ID: 16338019
    [Abstract] [Full Text] [Related]

  • 8. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L, Nuñez M, Mariño A, Alcocer F, Bonet L, García-Samaniego J, López-Serrano P, Cordero M, Portu J, Soriano V.
    AIDS; 2008 Jan 02; 22(1):15-21. PubMed ID: 18090387
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Peginterferon alpha-2b plus ribavirin with or without amantadine [correction of amantidine] for the treatment of non-responders to standard interferon and ribavirin.
    Hasan F, Al-Khaldi J, Asker H, Al-Ajmi M, Owayed S, Varghese R, Siddique I, Al-Nakib B.
    Antivir Ther; 2004 Aug 02; 9(4):499-503. PubMed ID: 15456080
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.
    Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxì A, Chaneac M, Reddy KR.
    J Hepatol; 2005 Sep 02; 43(3):425-33. PubMed ID: 15990196
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon.
    Aguilar Marucco D, Gonzalez de Requena D, Bonora S, Tettoni C, Bonasso M, De Blasi T, D'Avolio A, Sciandra M, Siccardi M, Baietto L, Trentini L, Sinicco A, Cariti G, Di Perri G.
    J Antimicrob Chemother; 2008 Apr 02; 61(4):919-24. PubMed ID: 18238889
    [Abstract] [Full Text] [Related]

  • 16. Gamma-glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon-alpha-2b in chronic hepatitis C non-responders.
    Bergmann JF, Vrolijk JM, van der Schaar P, Vroom B, van Hoek B, van der Sluys Veer A, de Vries RA, Verhey E, Hansen BE, Brouwer JT, Janssen HL, Schalm SW, de Knegt RJ.
    Liver Int; 2007 Nov 02; 27(9):1217-25. PubMed ID: 17919233
    [Abstract] [Full Text] [Related]

  • 17. Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients.
    Crespo M, Esteban JI, Ribera E, Falco V, Sauleda S, Buti M, Esteban R, Guardia J, Ocaña I, Pahissa A.
    AIDS; 2007 Feb 19; 21(4):477-81. PubMed ID: 17301566
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders.
    Sauleda S, Juárez A, Esteban JI, Altisent C, Ruiz I, Puig L, Esteban R, Guardia J.
    Hepatology; 2001 Nov 19; 34(5):1035-40. PubMed ID: 11679976
    [Abstract] [Full Text] [Related]

  • 20. Rationale and design of TeraViC-4 study: a phase III, randomized clinical trial to evaluate the effects of treatment duration with peginterferon alfa-2a (40-kDa) and ribavirin in naïve patients with chronic hepatitis C virus infection without early virological response at week 4.
    Sánchez-Tapias JM, Crespo J, Diago M, Pérez R, Romero-Gómez M, Muñoz-Sánchez M.
    Methods Find Exp Clin Pharmacol; 2002 Nov 19; 24(9):579-84. PubMed ID: 12616704
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.